AlloVir, Inc. (NasdaqCM: ALVR) Loss Submission Form

Kuznicki Law is investigating the proposed merger of AlloVir, Inc. (the “Company”) (NasdaqCM: ALVR) and Kalaris Therapeutics. Pursuant to the terms of the agreement, upon completion of the Merger, pre-Merger AlloVir stockholders are expected to own approximately 25.05% of the combined company. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to AlloVir shareholders.